Literature DB >> 31587870

The evaluation of Cannabidiol's effect on the immunotherapy of Burkitt lymphoma.

Tomiteru Togano1, Naomi Kim2, Natalie Kim2, Gabriel S Park3, Alex K Park2, Maura Bennet4, Jino Park5.   

Abstract

AIM: AF1q has a precise oncogenic function. The purpose of this study is to investigate whether CBD has an effect on the AF1q/ICAM-1 regulatory axis in Burkitt's lymphoma (BL), and thus has potential to enhance immunotherapy and reduce side effects.
METHODS: We established BL cell lines with altered AF1q expression using lentivirus. After confirmation of gene expression by RT-PCR, cells were treated with CBD followed by co-culture of killing assay.
RESULTS: AF1q increased oncogenic growth and colony formation, and induced resistance against cell-mediated cytotoxic chemotherapy through attenuation of ICAM-1 expression in BL. CBD was able to reverse the acquired resistance mediated by AF1q/ICAM-1 regulatory axis.
CONCLUSION: CBD holds potential to enhance the efficacy of immunotherapy for BL with hyperactive AF1q/ICAM-1 regulatory axis, and warrants further study.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AF1q; BL; Burkitt lymphoma; CBD; Cannabidiol; ICAM-1; Immunotherapy

Year:  2019        PMID: 31587870     DOI: 10.1016/j.bbrc.2019.10.001

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  2 in total

1.  The effects of cannabidiol via TRPV2 channel in chronic myeloid leukemia cells and its combination with imatinib.

Authors:  Federica Maggi; Maria Beatrice Morelli; Daniele Tomassoni; Oliviero Marinelli; Cristina Aguzzi; Laura Zeppa; Massimo Nabissi; Giorgio Santoni; Consuelo Amantini
Journal:  Cancer Sci       Date:  2022-03-04       Impact factor: 6.716

Review 2.  Pros and Cons of the Cannabinoid System in Cancer: Focus on Hematological Malignancies.

Authors:  Natasha Irrera; Alessandra Bitto; Emanuela Sant'Antonio; Rita Lauro; Caterina Musolino; Alessandro Allegra
Journal:  Molecules       Date:  2021-06-24       Impact factor: 4.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.